In 2025, the EPA DHA omega-3 ingredients market was valued at USD 3.40 billion. Based on Future Market Insights' analysis, demand for EPA DHA omega-3 ingredients is estimated to grow to USD 3.62 billion in 2026 and USD 6.80 billion by 2036. FMI projects a CAGR of 6.5% during the forecast period.
Absolute dollar growth of USD 3.18 billion over the decade reflects sustained clinical evidence accumulation supporting EPA and DHA omega-3 supplementation for cardiovascular, cognitive, infant brain development, and anti-inflammatory applications, driving dietary supplement, functional food, pharmaceutical, and infant formula demand across both established and emerging markets. Louis Dreyfus Company's October 2025 completion of the BASF Food and Health Performance Ingredients business acquisition, including the omega-3 oils portfolio for human nutrition, transfers BASF's established omega-3 production and formulation capabilities into LDC's global food and commodity ingredients distribution network. [1]
As the acquisition completion announcement noted, LDC 'successfully completed the sale of BASF's Food and Health Performance Ingredients Business,' with the transfer including omega-3 oils for human nutrition as a core component of the performance ingredients portfolio being integrated into LDC's food and health ingredients business. [1]
China leads growth at 8.8% CAGR through 2036, driven by expanding middle class dietary supplement consumption, regulatory approval for omega-3 health claims in functional food, and infant formula DHA fortification mandate enforcement. India grows at 8.1%, underpinned by rising omega-3 nutritional awareness, growing supplement retail, and expanding functional food penetration. Germany grows at 7.5%, France at 6.8%, the UK at 6.2%, the USA at 5.5%, and Brazil at 4.9%. DHA holds 53.6% of product share; Algae Oil accounts for 28.4% of source share; Dietary Supplements represent 37.2% of application value.
The EPA DHA omega-3 ingredients market encompasses the global production, trade, and commercial application of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as long-chain omega-3 polyunsaturated fatty acid ingredients sourced from marine oils including anchovy, sardine, tuna, salmon, cod liver, krill, and menhaden, from algae-based fermentation and cultivation producing DHA-rich algae oil, and from high-purity concentrates. The market covers EPA and DHA ingredients in oil, powder, and encapsulated forms for dietary supplement softgel and liquid fill, functional food fortification, pharmaceutical omega-3 prescription and OTC applications, infant formula and baby food DHA fortification, and pet food and animal feed omega-3 applications.
The report includes comprehensive global and regional market sizing by value with a 10-year forecast from 2026 to 2036. Segmental analysis covers product, source, and application dimensions. Country-level CAGR analysis includes China, India, Germany, France, the UK, the USA, and Brazil. Louis Dreyfus Company BASF omega-3 acquisition impact, KD Pharma Group dsm-firmenich food-grade oil acquisition, Aker BioMarine India market expansion with Revervia algae DHA, Corbion Chinese regulatory approval for algae DHA, and competitive positioning among Koninklijke DSM, BASF (legacy), Nordic Naturals, Clover Corporation, Omega Protein, and GC Rieber are incorporated.
The scope excludes short-chain omega-3 alpha-linolenic acid (ALA) from flaxseed oil, chia seed oil, and walnut oil that does not require conversion to EPA or DHA for commercial omega-3 ingredient classification. Plant-based ALA omega-3 oil products are excluded unless they specifically contain EPA or DHA fractions produced through algae fermentation or chemical concentration. Fish oil products containing less than 10% combined EPA and DHA by weight are outside the defined concentrate specification scope.
The EPA DHA Omega 3 ingredients market is expanding steadily due to growing consumer awareness about the health benefits of omega-3 fatty acids. Increasing focus on cardiovascular health, cognitive function, and overall wellness has driven demand for EPA and DHA enriched products. Innovations in sourcing and extraction techniques have improved ingredient purity and sustainability.
The rising preference for plant-based and clean-label products has fueled interest in algae oil as a sustainable and vegetarian source of omega-3s. Additionally, the dietary supplements segment has experienced consistent growth as consumers seek convenient ways to meet their nutritional needs.
Public health campaigns and dietary guidelines emphasizing omega-3 intake have further propelled market demand. Looking ahead, the market is expected to benefit from expanded applications across food and beverage sectors alongside supplements. Segmental growth is anticipated to be driven by DHA as the dominant product, algae oil as a key sustainable source, and dietary supplements as the primary application area.
The EPA DHA omega-3 ingredients market is segmented by product, source, and application and geographic regions. The product of the EPA DHA omega-3 ingredients market is divided into DHA and EPA. In terms of the source of the EPA DHA omega-3 ingredients, the market is classified into Algae oil, Anchovy/Sardine Oils, High concentrates, Medium Concentrates, Low concentrates, Tuna oil, Cod liver oil, Salmon oil, Krill oil, and Menhaden oil. Based on the application of the EPA DHA omega-3 ingredients, the market is segmented into Dietary Supplements, Functional Food, Pharmaceutical Food, Infant Food, Pet & Animal Feed, and Others. Regionally, the EPA DHA omega-3 ingredients industry is classified into North America, Latin America, Western Europe, Eastern Europe, Balkan & Baltic Countries, Russia & Belarus, Central Asia, East Asia, South Asia & Pacific, and the Middle East & Africa.
The DHA segment is projected to hold 53.6% of the market revenue in 2026, establishing it as the leading product category. This growth has been driven by DHA’s critical role in brain and eye health, which consumers and healthcare professionals have widely recognized. DHA is often preferred in formulations targeting maternal health, infant nutrition, and cognitive support, leading to increased inclusion in supplements and fortified foods.
Advances in extraction and concentration technologies have enhanced DHA bioavailability and stability. Furthermore, ongoing research highlighting DHA’s benefits has strengthened consumer trust and demand.
The segment benefits from its established health claims and regulatory approvals, reinforcing its position as a market leader.
The algae oil source segment is expected to account for 28.4% of the market revenue in 2026, reflecting growing interest in sustainable and plant-based omega-3 sources. Algae oil offers an environmentally friendly alternative to traditional fish oil, addressing concerns about overfishing and ocean pollution. The segment has been favored by vegan and vegetarian consumers as well as those seeking clean-label products.
Technological advancements have improved algae cultivation and extraction efficiencies, reducing production costs and enhancing product quality. Additionally, algae oil has been incorporated into a wide range of product formats including capsules, beverages, and functional foods.
As sustainability becomes a key purchasing factor, algae oil is expected to gain further traction as a preferred omega-3 source.
The dietary supplements application segment is projected to represent 37.2% of the market revenue in 2026, maintaining its leading role. Growth in this segment has been propelled by increasing consumer inclination toward proactive health management and nutritional supplementation. Dietary supplements offer a convenient and effective way to deliver EPA and DHA, meeting the daily recommended intake for various population groups.
The segment’s expansion has been supported by diverse product formats such as soft gels, gummies, and liquids that cater to different consumer preferences. Moreover, the rise in e-commerce and direct-to-consumer sales channels has facilitated easier access to omega-3 supplements globally.
As awareness about the benefits of omega-3 fatty acids continues to grow, the dietary supplements segment is expected to sustain its market dominance.
Demand for EPA DHA omega-3 ingredients is accelerating as dietary supplement, functional food, and infant formula sectors expand globally. Sales of algae- and fish-derived concentrates are gaining traction amid formulation innovation, regional regulatory shifts, and premium-positioned heart, brain, and prenatal health products.
Demand for high-purity EPA DHA omega-3 concentrates increased 19% in 2025, with formulators in Japan, Germany, and South Korea favoring microencapsulated powders for fortified beverages and dairy. Suppliers scaled up 70% EPA concentrates with oxidation levels below 5 meq/kg, targeting sports nutrition and brain health SKUs. USA brands launched gummies with triglyceride-form omega-3s showing 1.6× higher bioavailability than ethyl esters, prompting a 22% rise in repeat purchases. In India and Brazil, omega-3 fortified baby cereals and yogurts entered mid-tier retail channels, supported by oil-stabilization innovations that extended shelf life by 9 months under ambient conditions.
Sales of algal EPA DHA omega-3 rose 27% YoY in 2025 as plant-based nutrition trends converged with allergen-sensitive demand. Infant formula manufacturers in China and the EU switched from fish oil to algae-based DHA to meet clean-label and vegan certification requirements. Prenatal supplement brands adopted hexane-free algal oils, citing traceability and marine toxin avoidance. USA medical nutrition companies incorporated algae-derived omega-3s into parenteral emulsions and dysphagia-compatible formats, supported by GRAS and EFSA-compliant status. Production volumes in closed photobioreactors increased by 38%, lowering heavy metal risk and ensuring consistent EPA: DHA ratios for clinical and pharmaceutical applications.
.webp "Top Country Growth Comparison Epa Dha Omega 3 Ingredients Market Cagr (2026 2036)")
| Country | CAGR |
|---|---|
| China | 8.8% |
| India | 8.1% |
| Germany | 7.5% |
| France | 6.8% |
| UK | 6.2% |
| USA | 5.5% |
| Brazil | 4.9% |
The EPA-DHA omega-3 ingredients market is projected to grow globally at a CAGR of 6.5% from 2026 to 2036. China is setting the pace with a CAGR of 8.8%, fueled by rising nutraceutical production and domestic dietary supplement consumption. India follows at 8.1%, driven by growing functional food demand and a maturing clinical nutrition sector. Among OECD nations, Germany is progressing at 7.5%, reflecting strong pharma-grade EPA-DHA applications and consumer health awareness. The UK is expanding at a moderate 6.2%, supported by preventive healthcare focus and premium product uptake.
The USA is lagging slightly at 5.5%, where market maturity and strict regulatory compliance temper acceleration. This performance mix highlights how BRICS countries, particularly China and India, are scaling supply and demand faster, while OECD economies maintain steady momentum through innovation, clinical backing, and established retail channels in omega-3-based wellness. The report provides insights across 40+ countries. The five below are highlighted for their strategic influence and growth trajectory.
China’s EPA DHA omega-3 ingredients market is expected to grow at a CAGR of 8.8% between 2026 and 2036, driven by rising demand from functional foods, maternal nutrition, and pediatric health supplements. From 2020 to 2024, growth was primarily seen in fish oil capsules and imported prenatal supplements. Moving forward, the market is transitioning toward microencapsulated omega-3 powders and algal-based sources to meet clean-label and vegetarian consumer trends. Domestic supplement brands are scaling up R&D and in-house formulation of EPA-DHA blends to reduce reliance on imports and target health-conscious urban consumers.
India’s EPA DHA omega-3 ingredients market is projected to grow at a CAGR of 8.1% from 2026 to 2036, led by increased awareness of heart health and cognitive development supplements. During 2020-2024, omega-3 consumption remained niche, focused mostly in urban nutraceutical markets. The next decade is expected to witness broader penetration via fortified foods and personalized nutrition packs. Indian startups are launching value-priced fish oil capsules targeting middle-income groups, while contract manufacturers are introducing vegan omega-3 options derived from marine microalgae for Ayurvedic and holistic medicine lines.
Germany’s EPA DHA omega-3 ingredients market is projected to expand at a CAGR of 7.5% from 2026 to 2036, supported by strong demand for brain health and cardiovascular supplements among the aging population. Between 2020 and 2024, growth was driven by prescription omega-3 formulations and OTC supplements. In the coming years, dietary supplement companies are expected to launch EPA-DHA combinations with co-nutrients like vitamin D and CoQ10, targeting bioavailability and compliance. Consumer interest in sustainable sourcing is also pushing manufacturers to invest in Friend of the Sea-certified fish oils and algae-based solutions.
The EPA DHA omega-3 ingredients market in the United Kingdom is forecast to grow at a CAGR of 6.2% from 2026 to 2036, influenced by preventive health trends and clinical recommendations for omega-3 use in pregnancy and heart disease. From 2020 to 2024, demand stemmed mainly from the OTC supplement channel. Over the next decade, growth is expected to come from functional bakery, dairy fortification, and cognitive health-targeted gummies. Local nutraceutical brands are increasing imports of algal DHA concentrates for eco-friendly positioning, while regulatory clarity on EFSA claims is expected to boost market transparency.
The United States EPA DHA omega-3 ingredients market is projected to grow at a CAGR of 5.5% during the forecast period, supported by an aging population, sports nutrition trends, and prescription-grade omega-3 formulations. Between 2020 and 2024, consumption was driven by heart health supplements and fortified beverages. Going forward, omega-3 usage will expand through direct-to-consumer personalized nutrition services, as well as higher inclusion in protein bars and ready-to-drink shakes. Regulatory pressure for heavy metal testing is also reshaping sourcing practices, favoring refined fish oils and algae-based concentrates.
The EPA DHA omega-3 ingredients market is moderately concentrated and undergoing rapid structural change through acquisition. Koninklijke DSM holds an estimated 24.6% share in 2026, with BASF (now largely transferred to Louis Dreyfus Company), Nordic Naturals, Clover Corporation, Omega Protein, Copeinca, Solutex, Epax Norway, Croda International, Arista Industries, GC Rieber, OLVEA, and Lysi as significant competitors. Louis Dreyfus Company's October 2025 completion of the BASF Food and Health Performance Ingredients acquisition integrates BASF's established omega-3 formulation capabilities including microencapsulation technology and GRAS-certified concentrate production into LDC's global commodity and specialty ingredient distribution scale. [1]
KD Pharma Group's December 2025 agreement to acquire dsm-firmenich's food-grade oil distribution and supply business, following its earlier 2024 and 2025 consolidation of dsm-firmenich's marine lipids business and MEG-3 brand, positions KD Pharma as the largest pharmaceutical and nutraceutical omega-3 producer by combining dsm-firmenich's clinical-grade concentrate manufacturing with its own established pharmaceutical omega-3 production infrastructure. [2] Corbion's January 2026 Chinese regulatory approval for algae-based omega-3 DHA products opens the world's largest functional food and supplement market to algae DHA, providing Corbion with first-mover regulatory approval advantage in China's expanding infant formula and dietary supplement omega-3 ingredient demand.
Buyer concentration is high in the pharmaceutical omega-3 segment, where Amarin, AstraZeneca, and other prescription omega-3 drug producers require GMP-certified EPA and DHA concentrates at highly specific purity specifications. Dietary supplement contract manufacturers represent the broadest buyer base across omega-3 ingredient quality grades.
Recent Developments
| Metric | Value |
|---|---|
| Quantitative Units | USD 3.62 billion (2026) to USD 6.80 billion (2036), at a CAGR of 6.5% |
| Market Definition | The EPA DHA omega-3 ingredients market covers EPA and DHA long-chain omega-3 polyunsaturated fatty acid ingredients from marine oil, algae oil, and high-purity concentrate sources for dietary supplement, functional food, pharmaceutical, infant formula, and pet food applications. |
| Product Segmentation | DHA, EPA |
| Source Segmentation | Algae Oil, Anchovy/Sardine Oils, High Concentrates, Medium Concentrates, Low Concentrates, Tuna Oil, Cod Liver Oil, Salmon Oil, Krill Oil, Menhaden Oil |
| Application Segmentation | Dietary Supplements, Functional Food, Pharmaceutical Food, Infant Food, Pet and Animal Feed, Others |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa |
| Countries Covered | China, India, Germany, France, United Kingdom, United States, Brazil, Japan, South Korea, Australia and 40 plus countries |
| Key Companies Profiled | Koninklijke DSM N.V., BASF SE, Nordic Naturals Inc., Clover Corporation, Omega Protein, Copeinca ASA, Solutex, Epax Norway AS, Croda International Plc, Arista Industries Inc., GC Rieber, OLVEA, Lysi |
| Forecast Period | 2026 to 2036 |
| Approach | Hybrid bottom-up and top-down market modeling validated through primary interviews with EPA DHA omega-3 ingredient producers and dietary supplement contract manufacturers, supported by LDC and KD Pharma acquisition documentation and Aker BioMarine corporate expansion announcements |
How large is the EPA DHA Omega 3 Ingredients market in 2026?
Demand for EPA DHA Omega 3 Ingredients in the global market is estimated to be valued at USD 3.62 billion in 2026.
What will be the market size of EPA DHA Omega 3 Ingredients by 2036?
Market size for EPA DHA Omega 3 Ingredients is projected to reach USD 6.80 billion by 2036.
What is the expected CAGR for the EPA DHA Omega 3 Ingredients market?
Demand for EPA DHA Omega 3 Ingredients is expected to grow at a CAGR of 6.5% between 2026 and 2036.
Which product leads EPA DHA Omega 3 Ingredients demand?
DHA holds 53.6% of product share in 2026, driven by the priority clinical evidence base for DHA in infant brain and retinal development, adult cognitive function, and pregnancy nutrition that generates the highest-value application demand in infant formula DHA fortification and prenatal supplement formulations.
Which source is growing fastest in EPA DHA Omega 3 Ingredients?
Algae Oil accounts for 28.4% of source share in 2026 and is the fastest-growing source segment as algae DHA's fish-free, vegan, and sustainable positioning expands from vegetarian supplement consumers into mainstream infant formula, functional food, and pet nutrition applications where fish-free sourcing provides regulatory and consumer acceptance advantages.
What is the significance of LDC's acquisition of BASF's omega-3 business?
Louis Dreyfus Company's October 2025 completion of the BASF Food and Health Performance Ingredients acquisition transfers BASF's established omega-3 formulation capabilities and GRAS-certified concentrate production into LDC's global distribution network, reducing the number of independent production-scale omega-3 suppliers and creating a supplier concentration dynamic that procurement teams at supplement and infant formula manufacturers must actively manage through dual-qualification strategies.
Which country leads EPA DHA Omega 3 growth?
China leads at 8.8% CAGR through 2036, driven by expanding middle class dietary supplement consumption, regulatory approval for omega-3 health claims in functional food including Corbion's January 2026 Chinese algae DHA approval, and enforced infant formula DHA fortification mandates.
How does FMI validate its EPA DHA Omega 3 Ingredients forecast?
Forecast is developed using hybrid bottom-up and top-down modeling validated through primary interviews with omega-3 ingredient producers and supplement contract manufacturers, LDC and KD Pharma acquisition documentation, Aker BioMarine corporate expansion announcements, Corbion Chinese regulatory approval data, and Global Omega-3 Day 2026 industry reporting.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
EPA DHA Omega 3 Ingredients Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
